Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Please provide your email address to receive an email when new articles are posted on . The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

SAN FRANCISCO -- Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small ...

AstraZeneca Pharma India got CDSCO approval to market Durvalumab (Imfinzi) for unresectable hepatocellular carcinoma, ...

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ...

Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial. This is an ASCO Meeting ...

The median overall survival was 16.5 months with anlotinib plus penpulimab and 13.2 months with sorafenib. First-line treatment with anlotinib and penpulimab can improve survival outcomes when ...

Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...